93.50

5.34% 4.74

10 X Genomics Inc (TXG)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$88.76

Offen:

$90.04

24-Stunden-Volumen:

3.14M

Relative Volume:

1.04

Marktkapitalisierung:

$12.18B

Einnahmen:

$638.78M

Nettoeinkommen (Verlust:

$-22.66M

KGV:

-536.12

EPS:

-0.1744

Netto-Cashflow:

$122.18M

1W Leistung:

+9.09%

1M Leistung:

+51.66%

6M Leistung:

+318.72%

1J Leistung:

+659.55%

1-Tages-Spanne:

$88.14

$94.56

1-Wochen-Bereich:

$84.27

$95.16

52-Wochen-Spanne:

$11.16

$95.16

10 X Genomics Inc Stock (TXG) Company Profile

Firmenname

10 X Genomics Inc

Sektor

Healthcare (1064)

Branche

Health Information Services (46)

Telefon

(925) 401-7300

Adresse

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Mitarbeiter

1,178

Twitter

@10xgenomics

Nächster Verdiensttermin

2026-11-05

Neueste SEC-Einreichungen

TXG's Discussions on Twitter

Compare TXG vs VEEV, TEM, BTSG, HNGE

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TXG 10 X Genomics Inc	93.50	11.17B	638.78M	-22.66M	122.18M	-0.1744
VEEV Veeva Systems Inc	273.33	45.44B	3.32B	941.65M	1.64B	5.6161
TEM Tempus Ai Inc	76.63	15.43B	1.36B	-302.91M	-219.93M	-1.7182
BTSG Brightspring Health Services Inc	60.25	11.20B	13.65B	169.86M	412.12M	1.0758
HNGE Hinge Health Inc	97.67	7.71B	646.34M	-512.40M	202.76M	-6.6871

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-31	Hochstufung	William Blair	Mkt Perform → Outperform
2025-12-11	Herabstufung	Citigroup	Buy → Neutral
2025-12-02	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-09-11	Eingeleitet	Piper Sandler	Neutral
2025-02-13	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-09-03	Eingeleitet	Leerink Partners	Outperform
2024-07-22	Hochstufung	Jefferies	Hold → Buy
2024-07-18	Herabstufung	JP Morgan	Overweight → Neutral
2024-07-10	Herabstufung	Deutsche Bank	Buy → Hold
2024-06-27	Herabstufung	Wolfe Research	Outperform → Peer Perform
2024-06-25	Herabstufung	Guggenheim	Buy → Neutral
2024-06-03	Fortgesetzt	Jefferies	Hold
2024-05-01	Herabstufung	TD Cowen	Buy → Hold
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-12-12	Hochstufung	BofA Securities	Underperform → Neutral
2023-07-05	Fortgesetzt	JP Morgan	Overweight
2023-05-10	Eingeleitet	Barclays	Overweight
2023-03-31	Eingeleitet	Stephens	Overweight
2023-02-02	Eingeleitet	UBS	Neutral
2022-12-14	Eingeleitet	Deutsche Bank	Buy
2022-08-18	Herabstufung	Goldman	Neutral → Sell
2022-07-25	Eingeleitet	Canaccord Genuity	Buy
2022-07-15	Herabstufung	BofA Securities	Neutral → Underperform
2022-07-15	Herabstufung	William Blair	Outperform → Mkt Perform
2021-10-15	Fortgesetzt	Cowen	Outperform
2021-09-14	Herabstufung	BofA Securities	Buy → Neutral
2021-03-15	Eingeleitet	William Blair	Outperform
2020-12-02	Eingeleitet	Goldman	Neutral
2020-09-09	Eingeleitet	Morgan Stanley	Overweight
2020-07-10	Eingeleitet	Stifel	Buy
2020-03-05	Eingeleitet	Guggenheim	Buy
2020-01-07	Eingeleitet	Citigroup	Buy
2019-10-07	Eingeleitet	BofA/Merrill	Buy
2019-10-07	Eingeleitet	Cowen	Outperform
2019-10-07	Eingeleitet	JP Morgan	Overweight
2019-09-24	Eingeleitet	Evercore ISI	Outperform

Alle ansehen

10 X Genomics Inc Aktie (TXG) Neueste Nachrichten

Sep 30, 2026

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises - TradingView

Sep 30, 2026

Sep 29, 2026

10x Genomics, Inc. Announces Sentira, A New Cloud Analysis Platform - marketscreener.com

Sep 29, 2026

10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions - Morningstar

Sep 29, 2026

10x Genomics (TXG) Begins Global Shipments of Atera - TradingView

Sep 29, 2026